SpyGlass Pharma Reports Sustained 4-Year Results for BIM-IOL System
SpyGlass Pharma, Inc. (SGP) reported positive four-year first-in-human clinical trial results for its BIM-IOL System. Across all dose groups, intraocular pressure dropped by a mean of 37%, moving from 25.1 mmHg at baseline to 15.9 mmHg at 48 months. Shares of the company rose 2.50% to $24.60 following the update.
The four-year findings highlight durable eye pressure control without daily topical medication. Among 21 evaluable patients, 86% stayed entirely off drops at 48 months. In addition, 90% of participants preserved visual acuity of 20/25 or better, and the study recorded no product-related adverse events through four years.
The initial first-in-human trial is designed to track participants over a total seven-year follow-up period. Meanwhile, the company is actively advancing enrollment in its Phase 3 clinical trial.
Key points
- SpyGlass Pharma's BIM-IOL System achieved a 37% mean reduction in intraocular pressure over four years.
- At 48 months, 86% of evaluable patients remained completely off topical eye drops.
- No product-related adverse events were reported, and 90% of patients maintained visual acuity of 20/25 or better.
- The first-in-human trial will continue for seven years as Phase 3 enrollment progresses.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the 4-year trial results for SpyGlass Pharma?
The BIM-IOL System sustained a 37% mean reduction in eye pressure at 48 months, with 86% of evaluable patients off topical drops and zero product-related adverse events.
Is SpyGlass Pharma currently enrolling Phase 3 trials?
Yes, the company is actively enrolling patients in its Phase 3 trial while continuing to monitor initial study participants through a full seven-year follow-up period.